‘Ranbaxy got USFDA nod with no data or fraudulent data’

Ranbaxy Laboratories used ‘fraudulent’ data to get US Food and Drug Administration’s nod to sell its generic drugs, according to whistleblower Dinesh Thakur, who has also accused the drug-maker of faking test results.

In a interview to ‘CBS News’, he said: “The data is important because the FDA or other agencies globally look at that information to give you marketing authorisation to sell the drug.” 

An ex-employee of the company, Thakur, who was tasked with investigations of alleged malpractices in the Ranbaxy, further said: “We started getting the files, and, lo and behold, we find that none of that exists in the first place. . . It means that we’ve gotten approvals from the FDA to sell drugs that were based on no data, or data that was fraudulent.” 

Read the source article at Rediff.com

About the Author

Leave a Reply